COO’s Bold Buy Signals Acrivon’s Potential Upside Amid 68% YTD Decline
COO’s 10,000‑share buy of Acrivon Therapeutics signals a confidence shift amid a 67% YTD decline, hinting at a potential rebound with upcoming Phase 1 data.
3 minutes to read
Acrivon Therapeutics Inc